Stancu Andreea Lucia
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Harvard Institute of Medicine, 4 Blackfan Circle, Boston, MA, 02215, USA. E-mail:
Discoveries (Craiova). 2018 Sep 30;6(3):e84. doi: 10.15190/d.2018.4.
Recent studies indicate that the composition of gut bacteria can influence the effectiveness of certain cancer immunotherapy drugs and that modulating the gut microbiome may expand the pool of patients benefiting from cancer immunotherapies. Checkpoint blockade therapy has been effective on several types of malignancies (e.g. melanoma, lung cancer, kidney cancer). However, the number of patients that do not respond, or only partially respond, to cancer immunotherapy is high. Recently, several human and mouse studies have shown that gut microbiome may be a significant determinant of the response to cancer immunotherapy. This review focuses on the recent advances in our understanding of the interaction between human gut microbiome and response to immunotherapy in cancer. The gut microbiome may serve as a theranostic biomarker, by acting both as a useful prognostic biomarker and a target in cancer therapy.
最近的研究表明，肠道细菌的组成可以影响某些癌症免疫治疗药物的疗效，调节肠道微生物群可能会扩大受益于癌症免疫治疗的患者群体。检查点阻断疗法已对几种类型的恶性肿瘤（如黑色素瘤、肺癌、肾癌）有效。然而，对癌症免疫治疗无反应或仅部分反应的患者数量众多。最近，多项人体和小鼠研究表明，肠道微生物群可能是癌症免疫治疗反应的一个重要决定因素。本综述重点关注我们对人类肠道微生物群与癌症免疫治疗反应之间相互作用的最新认识进展。肠道微生物群可作为一种治疗诊断生物标志物，既作为有用的预后生物标志物，又作为癌症治疗的靶点。
